Problems in the Dextromethorphan-Bupropion (Auvelity) Evidence

November 14, 2026by Chris Aiken, MD0

Kevin Kennedy, MD

FDA reviewers judged a supporting trial negative, yet the journal published it as positive.

SEO EXCERPT:

LETTERS: Kennedy KP, Am J Psychiatry 2026; Response: Tabuteau H, Am J Psychiatry 2026.

STUDY TYPE: Letter to the editor and author response

FUNDING: Kennedy reports no industry ties; Tabuteau works for Axsome Therapeutics, the drug’s maker.

Background

Dextromethorphan-bupropion (Auvelity) won FDA approval for major depressive disorder in 2022. Bupropion blocks CYP2D6, raising blood levels of dextromethorphan, an NMDA-receptor antagonist. Approval rested on one placebo-controlled phase 3 trial (GEMINI) and a 97-patient phase 2 trial (ASCEND) that compared the combination with bupropion alone.

The usual standard for approval back the was two positive phase 3 trials, but Auvelity passed with a smaller, phase II trial because of its novel mechanism. Now Kevin Kennedy, a psychiatrist at University of Pennsylvania who runs a nice blog on psychiatric evidence, questions whether the phase II trial was even positive.

The Arguments

Kennedy raised several concerns, and Tabuteau answered each:

  • Four bupropion patients lacked dosing or follow-up ratings but stayed in the analysis. Without them, the benefts at week 6 lost significant, with the MADRS difference falling from 5.2 to 3.78 points. Tabuteau says the primary endpoint averaged weeks 1–6 and held up either way, but the FDA believed this averaging strategy over-estimated the benefits.
  • The protocol called ASCEND a “safety study,” meaning it wasn’t designed to test efficacy. The efficacy endpoints were added two weeks before the trial ended. Tabuteau says this hid the efficacy goal from sites to curb placebo response.
  • Independent raters added at week 22 excluded 24% of the bupropion arm versus 10% of the combination arm. This exclusion appears to favor the drug, but Tabuteau calls this standard practice.
  • The FDA rejected the trial’s last-observation-carried-forward imputation. Tabuteau says it preserved data.
  • Bupropion was dosed at only 105 mg twice daily, which is below the usual dose, raising questions about whether this was a fair comparison. However, that is the dose in Auvelity, and Tabuteau argues this matching allowed them to isolate dextromethorphan’s effect.
Practice Implications
  1. Auvelity’s approval rests on one standard trial, and one substandard.
  2. Notably, the medication failed in an unpublished trial of treatment resistant depression, the population it is often used for.
  3. Learn how to mind drug interactions when switching or starting Auvelity.

—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report

What’s Your Take? Share in Comments

Leave a Reply

Your email address will not be published. Required fields are marked *